These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

631 related items for PubMed ID: 27330072

  • 1. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
    Titecat M, Liang X, Lee CJ, Charlet A, Hocquet D, Lambert T, Pagès JM, Courcol R, Sebbane F, Toone EJ, Zhou P, Lemaitre N.
    J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D, Gülay Z, Akan OA, Aktaş Z, Kayacan CB, Cakici O, Eraç B, Gültekin M, Oğünç D, Söyletir G, Unal N, Uysal S.
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z, Kayacan C, Oncul O.
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [Abstract] [Full Text] [Related]

  • 5. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
    Sader HS, Rhomberg PR, Flamm RK, Jones RN, Castanheira M.
    J Antimicrob Chemother; 2017 Jun 01; 72(6):1696-1703. PubMed ID: 28333332
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of in-house and commercial real time-PCR based carbapenemase gene detection methods in Enterobacteriaceae and non-fermenting gram-negative bacterial isolates.
    Smiljanic M, Kaase M, Ahmad-Nejad P, Ghebremedhin B.
    Ann Clin Microbiol Antimicrob; 2017 Jul 10; 16(1):48. PubMed ID: 28693493
    [Abstract] [Full Text] [Related]

  • 10. [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009].
    Hamouche E, Sarkis DK.
    Pathol Biol (Paris); 2012 Jun 10; 60(3):e15-20. PubMed ID: 21719212
    [Abstract] [Full Text] [Related]

  • 11. Antibiotic resistance in gram-negative bacilli: a Singapore perspective.
    Tan TY, Hsu LY, Koh TH, Ng LS, Tee NW, Krishnan P, Lin RT, Jureen R.
    Ann Acad Med Singap; 2008 Oct 10; 37(10):819-25. PubMed ID: 19037514
    [Abstract] [Full Text] [Related]

  • 12. Prophylactic application of antibiotics selects extended-spectrum β-lactamase and carbapenemases producing Gram-negative bacteria in the oral cavity.
    Bratić V, Mihaljević S, Verzak Ž, Pleško E, Lukić A, Ćaćić M, Bedenić B.
    Lett Appl Microbiol; 2021 Aug 10; 73(2):206-219. PubMed ID: 33896011
    [Abstract] [Full Text] [Related]

  • 13. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
    Davies TA, Marie Queenan A, Morrow BJ, Shang W, Amsler K, He W, Lynch AS, Pillar C, Flamm RK.
    J Antimicrob Chemother; 2011 Oct 10; 66(10):2298-307. PubMed ID: 21775338
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
    Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ.
    Antimicrob Agents Chemother; 2009 Jun 10; 53(6):2360-6. PubMed ID: 19349512
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
    Zhou P, Hong J.
    Acc Chem Res; 2021 Apr 06; 54(7):1623-1634. PubMed ID: 33720682
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Structure-based discovery of LpxC inhibitors.
    Zhang J, Chan A, Lippa B, Cross JB, Liu C, Yin N, Romero JA, Lawrence J, Heney R, Herradura P, Goss J, Clark C, Abel C, Zhang Y, Poutsiaka KM, Epie F, Conrad M, Mahamoon A, Nguyen K, Chavan A, Clark E, Li TC, Cheng RK, Wood M, Andersen OA, Brooks M, Kwong J, Barker J, Parr IB, Gu Y, Ryan MD, Coleman S, Metcalf CA.
    Bioorg Med Chem Lett; 2017 Apr 15; 27(8):1670-1680. PubMed ID: 28302397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.